The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Secured for PFAS Remediation System

24 Jan 2023 07:00

RNS Number : 6110N
MyCelx Technologies Corporation
24 January 2023
 

24 January 2023

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Rental Contract Secured for PFAS Remediation System at Landfill

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce that it has secured a paid 6-month trial for treatment of PFAS in the United States. PFAS, which stands for per-fluoroalkyl and poly-fluoroalkyl compounds, are a collection of long-lasting manmade toxic chemicals which present a global threat to human health and the environment.

 

MYCELX has secured a contract for its fully containerized, mobile PFAS remediation system which includes MYCELX infused cartridge filtration and Performer™ media. The system will be utilized for treating PFAS contaminated leachate from a solid waste landfill. The rental is expected to successfully demonstrate the ability of the proprietary MYCELX technology to completely remove all identified PFAS chemicals to non-detectable concentrations in a single pass.

 

The revenue from this trial is not anticipated to alter management's revenue expectations for the year.

 

Connie Mixon, CEO, commented:

 

"We are pleased to announce this promising paid trial. The award is further proof of the strong momentum we are generating as a business in the PFAS solutions market, building on the Company's success with its previous trial in America and installations in Australia with an important distributor. In addition, in scenarios of solid waste landfill, we continue to see a growing demand for technologies that are able to treat the co-contaminants that are present with PFAS.

 

As a Group, we are firmly focused on achieving greater market share in three core areas; the Middle East, PFAS and REGEN. All of which we believe will be key growth drivers for MYCELX in 2023. We look forward to updating all our stakeholders on further corporate developments over the coming months."

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRANKNBKCBKDQDB
Date   Source Headline
28th Feb 20194:54 pmRNSResults of Fundraising
28th Feb 20197:00 amRNSProposed $1.8 million Placing
13th Feb 201910:22 amRNSTrading Update
21st Dec 20187:00 amRNSHolding(s) in Company
11th Dec 20187:15 amRNSDirectorate Changes
7th Dec 20187:00 amRNSBlock Admission Interim Update
29th Nov 20187:00 amRNSNew Project Award and Trading Update
8th Oct 20187:00 amRNSNew Project Award and Trading Update
12th Sep 20187:00 amRNSHalf Year Results Statement
27th Jul 20187:00 amRNSContract Extension in Saudi Arabia
11th Jul 20181:16 pmRNSResult of Annual Meeting
7th Jun 20184:23 pmRNSBlock listing Interim Review
7th Jun 20183:42 pmRNSAnnual Financial Report
15th May 20187:00 amRNSFinal Results for the year ending 31 December 2017
19th Apr 20187:00 amRNSNew Purchase Order Award and Equipment Sale
13th Apr 201810:18 amRNSIssue of Equity
10th Apr 20187:00 amRNSPurchase Order Award & General Manager Appointment
28th Mar 201812:48 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSIssue of Equity
6th Feb 20187:00 amRNSExtension of Contract and New Project
17th Jan 20187:00 amRNSTrading Update
7th Dec 20179:46 amRNSBlock listing Interim Review
3rd Nov 201712:39 pmRNSIssue of Equity
26th Oct 20177:30 amRNSHolding(s) in Company
9th Oct 20177:00 amRNSIssue of Equity
27th Sep 20172:44 pmRNSApplication for Block Admission
26th Sep 20175:31 pmRNSClosure of Restricted Stock Line
21st Sep 20177:00 amRNSConsolidation of Stock Lines
13th Sep 20177:00 amRNSHalf Year Results Statement
12th Jul 201712:30 pmRNSResult of Annual Meeting
7th Jul 20177:00 amRNSHalf Year Trading Update
9th Jun 201710:00 amRNSMailing of Annual Financial Report & GM Notice
7th Jun 201710:30 amRNSBlock listing Interim Review
30th May 20171:19 pmRNSDirector/PDMR Shareholding
26th May 20177:00 amRNSContract win with new SABIC affiliate customer
11th May 20177:00 amRNSFinal Results for the year ending 31 December 2016
8th May 20177:00 amRNSContract Award & Notification of Full Year Results
30th Jan 20177:00 amRNSTrading Update
7th Dec 20162:34 pmRNSBlock listing Interim Review
4th Oct 20167:00 amRNSAppointment of Nominated Adviser & Broker
14th Sep 20167:00 amRNSHalf Year Results Statement
13th Jul 20164:21 pmRNSResult of AGM
11th Jul 20167:00 amRNSHalf Year Trading Update
30th Jun 20167:00 amRNSHolding(s) in Company
24th Jun 20167:00 amRNSMyCelx and Schlumberger Sign Upstream Agreement
9th Jun 20167:00 amRNSMailing of 2015 Annual Report and Notice of AGM
7th Jun 20163:32 pmRNSBlock listing Interim Review
17th May 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSAppointment of CFO/Grant of Share Options
4th Mar 20161:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.